CD8A and neoplasm: Overall, this analysis suggests that the addition of the vaccine to CAR-T therapy increases the anti-tumor potential of tumor-infiltrating CD8+ T-cells and skews the differentiation of tumor-infiltrating CD4+ T-cells to a Th1 phenotype.